BridgeBio Pharma, Inc. Increase (Decrease) in Prepaid Expense and Other Assets
BridgeBio Pharma, Inc. (BBIO) reported Increase (Decrease) in Prepaid Expense and Other Assets of $20.23 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-10
- BridgeBio Pharma, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was $1.38M, a 93.79% decline year-over-year.
- BridgeBio Pharma, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was $18.84M, a 3769.61% increase year-over-year.
- BridgeBio Pharma, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was -$8.75M.
- BridgeBio Pharma, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was -$5.22M, a 147.28% decline year-over-year.
- BridgeBio Pharma, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2025 was $8.78M, a 36.94% decline from fiscal 2024.
- BridgeBio Pharma, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2024 was $13.92M, a 415.10% increase from fiscal 2023.
- BridgeBio Pharma, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2023 was $2.70M.
- BridgeBio Pharma, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2022 was -$7.67M, a 279.99% decline from fiscal 2021.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 3 month as first filed | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $20.23M 10-Q · filed 2026-08-10 | $11.48M derived: sum of 3 quarters · filed 2026-08-10 | $6.26M derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2026-03-31 | $18.84M 10-Q · filed 2026-05-07 | $10.10M derived: sum of 2 quarters · filed 2026-05-07 | $4.88M derived: sum of 3 quarters · filed 2026-05-07 | $27.14M derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2025-12-31 | -$8.75M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$13.97M derived: sum of 2 quarters · filed 2026-02-24 | $8.29M derived: sum of 3 quarters · filed 2026-08-10 | $8.78M 10-K · filed 2026-02-24 | ||
| 2025-09-30 | -$5.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $17.04M derived: sum of 2 quarters · filed 2026-08-10 | $17.53M 10-Q · filed 2025-10-29 | $13.90M derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2025-06-30 | $22.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $22.75M 10-Q · filed 2026-08-10 | $19.12M derived: sum of 3 quarters · filed 2026-08-10 | $30.16M derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2025-03-31 | $487.00K 10-Q · filed 2026-05-07 | -$3.14M derived: sum of 2 quarters · filed 2026-05-07 | $7.90M derived: sum of 3 quarters · filed 2026-05-07 | $11.06M derived: sum of 4 quarters · filed 2026-05-07 | ||
| 2024-12-31 | -$3.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $7.41M derived: sum of 2 quarters · filed 2026-02-24 | $10.57M derived: sum of 3 quarters · filed 2026-02-24 | $13.92M 10-K · filed 2026-02-24 | ||
| 2024-09-30 | $11.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $14.20M derived: sum of 2 quarters · filed 2025-10-29 | $17.54M 10-Q · filed 2025-10-29 | $19.27M derived: sum of 4 quarters · filed 2026-02-24 | ||
| 2024-06-30 | $3.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $6.51M 10-Q · filed 2025-08-05 | $8.23M derived: sum of 3 quarters · filed 2026-02-24 | $10.27M derived: sum of 4 quarters · filed 2026-02-24 | ||
| 2024-03-31 | $3.35M 10-Q · filed 2025-04-29 | $5.07M derived: sum of 2 quarters · filed 2026-02-24 | $7.10M derived: sum of 3 quarters · filed 2026-02-24 | $2.50M derived: sum of 4 quarters · filed 2026-02-24 | ||
| 2023-12-31 | $1.72M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $3.76M derived: sum of 2 quarters · filed 2026-02-24 | -$840.00K derived: sum of 3 quarters · filed 2026-02-24 | $2.70M 10-K · filed 2026-02-24 | ||
| 2023-09-30 | $2.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$2.56M derived: sum of 2 quarters · filed 2024-11-12 | $980.00K 10-Q · filed 2024-11-12 | -$2.62M derived: sum of 4 quarters · filed 2025-02-20 | ||
| 2023-06-30 | -$4.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | -$1.06M 10-Q · filed 2024-08-01 | -$4.66M derived: sum of 3 quarters · filed 2025-02-20 | -$11.75M derived: sum of 4 quarters · filed 2025-02-20 | ||
| 2023-03-31 | $3.54M 10-Q · filed 2024-05-02 | -$57.00K derived: sum of 2 quarters · filed 2025-02-20 | -$7.15M derived: sum of 3 quarters · filed 2025-02-20 | -$6.79M derived: sum of 4 quarters · filed 2025-02-20 | ||
| 2022-12-31 | -$3.60M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | -$10.69M derived: sum of 2 quarters · filed 2025-02-20 | -$10.33M derived: sum of 3 quarters · filed 2025-02-20 | -$7.67M 10-K · filed 2025-02-20 | ||
| 2022-09-30 | -$7.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$6.73M derived: sum of 2 quarters · filed 2023-11-02 | -$4.07M 10-Q · filed 2023-11-02 | -$3.55M derived: sum of 4 quarters · filed 2024-02-22 | ||
| 2022-06-30 | $364.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $3.02M 10-Q · filed 2023-08-03 | $3.54M derived: sum of 3 quarters · filed 2024-02-22 | $8.68M derived: sum of 4 quarters · filed 2024-02-22 | ||
| 2022-03-31 | $2.66M 10-Q · filed 2023-05-04 | $3.18M derived: sum of 2 quarters · filed 2024-02-22 | $8.32M derived: sum of 3 quarters · filed 2024-02-22 | $8.37M derived: sum of 4 quarters · filed 2024-02-22 | ||
| 2021-12-31 | $519.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $5.66M derived: sum of 2 quarters · filed 2024-02-22 | $5.71M derived: sum of 3 quarters · filed 2024-02-22 | $4.26M 10-K · filed 2024-02-22 | ||
| 2021-09-30 | $5.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $5.19M derived: sum of 2 quarters · filed 2022-11-03 | $3.74M 10-Q · filed 2022-11-03 | $5.41M derived: sum of 4 quarters · filed 2023-02-23 | ||
| 2021-06-30 | $48.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$1.40M 10-Q · filed 2022-08-04 | $268.00K derived: sum of 3 quarters · filed 2023-02-23 | $7.29M derived: sum of 4 quarters · filed 2023-02-23 | ||
| 2021-03-31 | -$1.45M 10-Q · filed 2022-05-05 | $220.00K derived: sum of 2 quarters · filed 2023-02-23 | $7.25M derived: sum of 3 quarters · filed 2023-02-23 | $5.61M derived: sum of 4 quarters · filed 2023-02-23 | ||
| 2020-12-31 | $1.67M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $8.69M derived: sum of 2 quarters · filed 2023-02-23 | $7.06M derived: sum of 3 quarters · filed 2023-02-23 | $7.06M 10-K · filed 2023-02-23 | ||
| 2020-09-30 | $7.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $5.39M derived: sum of 2 quarters · filed 2021-11-04 | $5.39M 10-Q · filed 2021-11-04 | $3.50M derived: sum of 4 quarters · filed 2022-02-25 | ||
| 2020-06-30 | -$1.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | -$1.63M 10-Q · filed 2021-08-05 | -$3.53M derived: sum of 3 quarters · filed 2022-02-25 | $5.67M derived: sum of 4 quarters · filed 2022-02-25 | ||
| 2020-03-31 | -$1.00K 10-Q · filed 2021-05-06 | -$2.85M 10-Q · filed 2020-05-14 | -$1.90M derived: sum of 2 quarters · filed 2022-02-25 | $7.30M derived: sum of 3 quarters · filed 2022-02-25 | $10.34M derived: sum of 4 quarters · filed 2022-02-25 | |
| 2019-12-31 | -$1.89M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $7.30M derived: sum of 2 quarters · filed 2022-02-25 | $10.34M derived: sum of 3 quarters · filed 2022-02-25 | $10.65M 10-K · filed 2022-02-25 | $13.49M 10-K · filed 2020-03-03 | |
| 2019-09-30 | $9.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $12.23M derived: sum of 2 quarters · filed 2020-11-05 | $12.54M 10-Q · filed 2020-11-05 | $6.98M derived: sum of 4 quarters · filed 2021-02-25 | ||
| 2019-06-30 | $3.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11 | $3.35M 10-Q · filed 2020-08-11 | -$2.22M derived: sum of 3 quarters · filed 2021-02-25 | |||
| 2019-03-31 | $309.00K 10-Q · filed 2020-05-14 | -$5.25M derived: sum of 2 quarters · filed 2021-02-25 | ||||
| 2018-12-31 | -$5.56M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $6.10M 10-K · filed 2021-02-25 | ||||
| 2018-09-30 | $11.66M 10-Q · filed 2019-11-08 | |||||
| 2017-12-31 | $4.30M 10-K · filed 2020-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |